Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), Verastem (VSTM) and Align Tech (ALGN)

Tipranks - Tipranks - Fri Mar 6, 7:02AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cross Country Healthcare (CCRN – Research Report), Verastem (VSTM – Research Report) and Align Tech (ALGN – Research Report).

Claim 70% Off TipRanks Premium

Cross Country Healthcare (CCRN)

In a report released today, Tobey Sommer from Truist Financial reiterated a Hold rating on Cross Country Healthcare. The company’s shares closed last Wednesday at $9.13.

According to TipRanks.com, Sommer is a 5-star analyst with an average return of 7.2% and a 59.7% success rate. Sommer covers the Industrial Goods sector, focusing on stocks such as Andersen Group, Inc. Class A, Amentum Holdings, Inc., and Icf International. ;'>

Cross Country Healthcare has an analyst consensus of Hold, with a price target consensus of $11.33, which is a 25.7% upside from current levels. In a report released today, William Blair also maintained a Hold rating on the stock.

See the top stocks recommended by analysts >>

Verastem (VSTM)

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Verastem, with a price target of $15.00. The company’s shares closed last Wednesday at $5.81.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 14.9% and a 50.6% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verastem with a $16.20 average price target, representing a 182.2% upside. In a report issued on February 19, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.

Align Tech (ALGN)

Piper Sandler analyst Jason Bednar maintained a Buy rating on Align Tech today and set a price target of $220.00. The company’s shares closed last Wednesday at $182.16, close to its 52-week low of $157.57.

According to TipRanks.com, Bednar has 0 stars on 0-5 stars ranking scale with an average return of -4.5% and a 40.3% success rate. Bednar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Merit Medical Systems, and Solventum Corporation. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $201.70 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).